Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01017042 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of an Acute Gout Regimen
A Phase 1 study, sponsored by Mutual Pharmaceutical Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01017042 is a Phase 1 study that has completed, run by Mutual Pharmaceutical Company. The registered enrollment target is 13 participants.
The verdict
NCT01017042, a Phase 1 study, has completed, sponsored by Mutual Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study aims to characterize the pharmacokinetic profile of colchicine after a regimen of 1.8 mg over two hours. A secondary goal is to evaluate the safety and tolerability of this regimen in healthy volunteers. To this end, all study subjects will be monitored for adverse effects throughout the entire study period.
Interventions
- DRUG colchicine tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-09 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01017042
The ClinicalTrials.gov registry entry for NCT01017042 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mutual Pharmaceutical Company, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which colchicine tablets is the first listed.
NCT01017042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01017042 about?
NCT01017042 is a clinical study titled "Pharmacokinetic Study of an Acute Gout Regimen". This study aims to characterize the pharmacokinetic profile of colchicine after a regimen of 1.8 mg over two hours. A secondary goal is to evaluate the safety and tolerability of this regimen in healthy volunteers. To this end, all study subjects will be monitored for adverse effects throughout the ...
What is the current status of trial NCT01017042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2007-09. Estimated completion is 2007-10.
What interventions are being tested in trial NCT01017042?
The interventions under investigation include: colchicine tablets (DRUG).
Who is sponsoring clinical trial NCT01017042?
This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.